Yes, Artificial Intelligence (AI) and Neural Machine Translation (NMT) can be utilized in medical device translation to accelerate timelines and reduce costs. However, strict regulatory frameworks like the EU Medical Device Regulation (MDR) require absolute accuracy to ensure patient safety. Therefore, a “Human-in-the-Loop” (HITL) approach—where qualified subject-matter experts review and post-edit AI-generated translations—is non-negotiable for critical materials like Instructions for Use (IFUs), labeling, and software interfaces.

As a senior-level expert navigating the global medical device landscape, I observe a recurring theme in boardroom discussions: the pressure to reduce time-to-market while simultaneously cutting localization costs. Artificial Intelligence (AI) has emerged as the panacea for these challenges. Modern Neural Machine Translation (NMT) engines, powered by Large Language Models (LLMs), produce outputs that read fluidly and grammatically correctly. For global market access teams, the temptation to feed Instructions for Use (IFUs), clinical trial protocols, and marketing collateral into an AI engine is immense.

However, fluid does not always mean accurate. In the life sciences sector, the delta between “mostly correct” and “completely accurate” is the difference between a successful product launch and a catastrophic adverse event. This is why AI, while a powerful tool, cannot operate in a vacuum. It requires a rigorous, systematic Human-in-the-Loop (HITL) framework.

The regulatory landscape for medical devices is uncompromising. The European Union Medical Device Regulation (EU MDR 2017/745) mandates that information supplied by the manufacturer (including IFUs and labeling) must be provided in the official Union language(s) determined by the Member State in which the device is made available. Furthermore, the translation must be precise, unambiguous, and easily understood by the intended user—whether that is a seasoned cardiovascular surgeon or a layperson using a home diagnostic kit.

AI models lack true comprehension. They predict the next most likely word based on training data. They do not understand the anatomical nuances of a surgical procedure or the clinical implications of a misstated dosage. If an AI engine mistranslates “intravenous” as “intra-arterial,” the grammatical structure of the sentence remains perfect, but the clinical outcome is fatal. Regulatory bodies like the FDA and the EMA do not accept “AI hallucination” as a valid excuse for non-compliance or patient harm.

Human-in-the-Loop (HITL) is an integrated workflow that leverages the speed of AI while anchoring the output in human expertise and risk management. In the localization industry, this is formally recognized under ISO 18587 (Post-editing of machine translation output). HITL involves several critical stages:

  1. Pre-processing and Terminology Management: Before AI touches the text, specialized glossaries and Translation Memory (TM) databases are locked in. This forces the AI to use approved medical terminology.
  2. NMT Engine Processing: The text is processed using engines specifically trained on life sciences data, not generic public translation tools.
  3. Subject Matter Expert (SME) Post-Editing: This is the crucial human element. Linguists with proven medical backgrounds review the output line-by-line. They look for clinical accuracy, tone, and cultural appropriateness.
  4. In-Country Review (ICR): Local medical professionals validate the translated content to ensure it aligns with regional medical practices and regulatory expectations.
MethodologySpeedCostRisk of Clinical ErrorRegulatory Compliance
Raw AI TranslationInstantaneousVery LowHighNon-Compliant
Traditional Human TranslationSlowerPremiumVery LowFully Compliant
AI + Human-in-the-Loop (HITL)FastOptimizedVery LowFully Compliant

Partnering with a language service provider that understands the gravity of the medical device industry is critical. Ingenuiti does not view AI as a replacement for human expertise; rather, we view it as an accelerator. By combining state-of-the-art AI technology with a robust, ISO-certified network of medical linguists, Ingenuiti delivers translations that meet the rigorous safety and compliance standards of the global market. Our HITL process ensures that every localized IFU, UI string, and compliance document is accurate, culturally resonant, and audit-ready.

Can we use generic AI tools for translating medical device manuals?

No. Generic AI tools lack the specialized medical training data, terminology enforcement, and data security protocols required for life sciences. Using them introduces severe regulatory and patient safety risks.

What is Post-Editing Machine Translation (PEMT)?

PEMT is the process where human linguists review and correct machine-generated translations. In the medical device industry, “Full PEMT” is required to ensure the text is clinically accurate and stylistically appropriate.

How does HITL impact localization budgets?

HITL offers a balanced approach. It reduces the per-word cost and turnaround time compared to traditional translation from scratch, while maintaining the high quality and compliance required by regulatory bodies.

Ready to accelerate your device’s global market entry without risking regulatory compliance? [Partner with Ingenuiti today] to implement an ISO-certified, Human-in-the-Loop translation workflow that guarantees accuracy, speeds up time-to-market, and keeps your patient-facing materials audit-ready.

Picture of Adam Eling

Adam Eling

Adam Eling is the Vice President of Client Services at Ingenuiti, where he leverages over 15 years of expertise to drive global learning strategies. A seasoned speaker and industry thought leader, Adam is recognized for his "curiosity-first" approach to solving complex L&D challenges. Based in Charleston, SC, he balances his passion for the evolving education landscape with family time, hiking, and the outdoors.

Share on social:

Contact
Ingenuiti Today

Schedule a free, 15-minute discovery call to discuss your needs.